| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Division of Oncology, The Children’s Hospital of Philadelphia and Department of Pediatrics, The University of Pennsylvania, Philadelphia, Pennsylvania 19104 [A. E., M. A. G., N. I., X-g. L., A. E. E., G. M. B.]; University Children’s Hospital of Essen, 45122 Essen, Germany [A. E.]; and University Children’s Hospital of Zurich, 8032 Zurich, Switzerland [M. A. G.]
Angiogenesis is essential for tumor growth and metastasis and depends on the production of angiogenic factors. Mechanisms regulating the expression of angiogenic factors in tumor cells are largely unknown. High expression of the neurotrophin receptor TrkA in neuroblastomas (NBs) is associated with a favorable prognosis, whereas TrkB is mainly expressed on aggressive, MYCN-amplified NBs. To investigate the biological effects of TrkA and TrkB expression on angiogenesis in NB, we examined the expression of angiogenic factors in the human NB cell line SY5Y and its TrkA and TrkB transfectants. In comparison with parental SY5Y cells, mRNA and protein levels of the examined angiogenic factors were significantly reduced in SY5Y-TrkA cells, whereas SY5Y-TrkB cells did not demonstrate a significant change. Conditioned medium of TrkB transfectants and parental SY5Y cells induced endothelial cell proliferation and migration, but this effect was completely absent in SY5Y-TrkA cells. TrkA expression also resulted in severely impaired tumorigenicity in a mouse xenograft model and was associated with reduced angiogenic factor expression and vascularization of tumors, as determined by immunohistochemistry and an in vivo Matrigel assay. TrkA expression inhibits angiogenesis and tumor growth in SY5Y NB cells by down-regulation of angiogenic factors, whereas expression of TrkB does not down-regulate the production of these angiogenic factors. The biologically different behavior of TrkA- and TrkB-expressing NBs may be explained in part by their effects on angiogenesis.
This article has been cited by other articles:
|
|
 |
|
  G. M. Brodeur, J. E. Minturn, R. Ho, A. M. Simpson, R. Iyer, C. R. Varela, J. E. Light, V. Kolla, and A. E. Evans Trk Receptor Expression and Inhibition in Neuroblastomas Clin. Cancer Res., May 15, 2009; 15(10): 3244 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Caporali and C. Emanueli Cardiovascular Actions of Neurotrophins Physiol Rev, January 1, 2009; 89(1): 279 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ikegaki, T. Gotoh, B. Kung, J. S. Riceberg, D. Y. Kim, H. Zhao, E. F. Rappaport, S. L. Hicks, R. C. Seeger, and X. X. Tang De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene Clin. Cancer Res., October 15, 2007; 13(20): 6001 - 6009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakamura, K. C. Martin, J. K. Jackson, K. Beppu, C.-W. Woo, and C. J. Thiele Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells. Cancer Res., April 15, 2006; 66(8): 4249 - 4255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. X. Tang, H. Zhao, B. Kung, D. Y. Kim, S. L. Hicks, S. L. Cohn, N.-K. Cheung, R. C. Seeger, A. E. Evans, and N. Ikegaki The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma. Cancer Res., March 1, 2006; 66(5): 2826 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aoyama, T. Ozaki, H. Inuzuka, D. Tomotsune, J. Hirato, Y. Okamoto, H. Tokita, M. Ohira, and A. Nakagawara LMO3 Interacts with Neuronal Transcription Factor, HEN2, and Acts as an Oncogene in Neuroblastoma Cancer Res., June 1, 2005; 65(11): 4587 - 4597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sitek, O. Apostolov, K. Stuhler, K. Pfeiffer, H. E. Meyer, A. Eggert, and A. Schramm Identification of Dynamic Proteome Changes Upon Ligand Activation of Trk-Receptors Using Two-dimensional Fluorescence Difference Gel Electrophoresis and Mass Spectrometry Mol. Cell. Proteomics, March 1, 2005; 4(3): 291 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. X. Tang, M. E. Robinson, J. S. Riceberg, D. Y. Kim, B. Kung, T. B. Titus, S. Hayashi, A. W. Flake, D. Carpentieri, and N. Ikegaki Favorable Neuroblastoma Genes and Molecular Therapeutics of Neuroblastoma Clin. Cancer Res., September 1, 2004; 10(17): 5837 - 5844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Beppu, J. Jaboine, M. S. Merchant, C. L. Mackall, and C. J. Thiele Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression J Natl Cancer Inst, January 7, 2004; 96(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-W. Yang, S. Liu, Y. Tian, H. R. Salwen, A. Chlenski, J. Weinstein, and S. L. Cohn Methylation-associated Silencing of the Thrombospondin-1 Gene in Human Neuroblastoma Cancer Res., October 1, 2003; 63(19): 6299 - 6310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis Cancer Res., December 15, 2002; 62(24): 7357 - 7363. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
